Pharmacologic Targeting of Regulatory T Cells for Solid Organ Transplantation: Current and Future Prospects

摘要: The last three decades have witnessed significant advances in the development of immunosuppressive medications used kidney transplantation leading to a remarkable gain short-term graft function and outcomes. Despite these major breakthroughs, improvements long-term outcomes lag behind due stalemate between drug-related nephrotoxicity chronic rejection typically donor-specific antibodies. Regulatory T cells (Tregs) been shown modulate alloimmune response can exert suppressive activity preventing allograft transplantation. Currently available agents impact Tregs milieu with some interactions being deleterious while others may be beneficial. Variable effects are seen common antibody induction such that basiliximab, an IL-2 receptor blocker, decreases lymphocyte depleting as antithymocyte globulin increase Tregs. Calcineurin inhibitors, mainstay maintenance immunosuppression since mid-1980s, seem suppress mammalian targets rapamycin (less commonly regimens) expand purpose this review is provide overview Treg biology transplantation, identify more detail lastly describe future directions use themselves therapy for tolerance induction.